It is reported the case of a 12-year-old white school boy with diagnosis of degree III hemophilia A since he was 2 months old that had received innumerable transfusions of cryoprecipitate and several of blood. In 1999, he was diagnosed hepatitis C and, at the end of 2000, HIV infection. There was a high possibility of having acquired them both by the blood and hemoderivative transfusions received. As very low figures of TCD4 lymphocytes (4%) with 54 cells/mm3 were corroborated on conducting immunological studies, it was classified as group B-3 AIDS, according to the classification established by the CDC of Atlanta, in 1994. He was indicated antiretroviral treatment with tritherapy (d4T, 3TC and Nelfinavir). This case was reported to call the attention of doctors at the time of indicating treatment with antivirals or protease-inhibitors to fight AIDS in pediatric cases with diagnosis of hemophilia, since some of them may cause spontaneous bleeding episodes.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Deep analysis of the major histocompatibility complex genetic associations using covariate analysis and haploblocks unravels new mechanisms for the molecular etiology of Elite Control in AIDS.
BMC Immunol
January 2025
Laboratoire Génomique, Bioinformatique, et Chimie Moléculaire, Conservatoire National des Arts et Métiers, 2 rue Conté 75003, Paris, EA7528, France.
Introduction: We have reanalyzed the genomic data from the International Collaboration for the Genomics of HIV (ICGH), focusing on HIV-1 Elite Controllers (EC).
Methods: A genome-wide association study (GWAS) was performed, comparing 543 HIV-1 EC individuals with 3,272 uninfected controls (CTR) of European ancestry. 8 million single nucleotide polymorphisms (SNPs) and HLA class I and class II gene alleles were imputed to compare EC and CTR.
Non-acquired immunodeficiency syndrome defining malignancies in people living with haemophilia and human immunodeficiency virus after direct-acting antiviral era.
Glob Health Med
October 2024
Division of Infectious Diseases, Advanced Clinical Research Centre, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Article Synopsis
- The study investigates non-acquired immunodeficiency syndrome-defining malignancies (NADMs) among people living with hemophilia and HIV in Japan, focusing on the period after the approval of direct-acting antivirals for hepatitis C virus (HCV).
- A nationwide survey was conducted across 395 HIV treatment facilities, collecting data on 328 individuals from 2015 to 2022, which revealed that liver cancer was the most common NADM, accounting for 43% of cases identified.
- The findings indicate a significantly higher rate of liver cancer and other malignancies in this population, particularly in younger patients, emphasizing the importance of regular cancer screening and preventive strategies for PLWH
Biological Barriers for Drug Delivery and Development of Innovative Therapeutic Approaches in HIV, Pancreatic Cancer, and Hemophilia A/B.
Pharmaceutics
September 2024
WIR-Walk In Ruhr, Center for Sexual Health & Medicine, Department of Dermatology, Venerology and Allergology, Ruhr-University Bochum, 44787 Bochum, Germany.
Article Synopsis
- Biological barriers pose significant challenges in the development of new therapies, as drugs must navigate various protective layers at both the tissue and cellular levels to effectively target specific cells.
- A diverse range of therapeutic options is now available, from small molecules to advanced techniques like gene therapies and monoclonal antibodies, with recent innovations rapidly transforming treatment approaches.
- Notable advancements, such as the FDA approval of new RNA-based therapies and viral-vector gene therapies for hemophilia, exemplify the potential for innovative medicines to address complex diseases and improve patient care.
Prevalence and associated factors of low vigor in patients living with HIV and hemophilia in Japan: A cross-sectional observational study.
Glob Health Med
June 2024
Department of Psychiatry, Hitachi Medical Education and Research Center, University of Tsukuba Hospital, Ibaraki, Japan.
People living with human immunodeficiency virus (HIV) are at high risk of mental health problems. However, little is known about this risk in HIV-infected patients with hemophilia (HPH) who contracted the virus through blood products. This cross-sectional, observational study assessed patients' mood states and the factors associated with them among Japanese HPH to evaluate the need for psychosocial support.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated the use of engineered outer membrane vesicles (OMVs) from ClearColi™ as both an adjuvant and a carrier for a novel vaccine targeting HIV-1 antigens Nef and Nef-Tat.
- Researchers isolated recombinant OMVs (rOMVs) containing specific fusion proteins and confirmed their presence through western blotting.
- Results showed that rOMVs induced stronger immune responses, including higher levels of IgG2a and IFN-γ, compared to traditional adjuvants, indicating their potential as effective vaccine carriers against HIV-1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!